Diabetes drug (Bydureon) Showed Potential as Disease-modifying Therapy for Parkinson’s: More Research Needed

Diabetes drug (Bydureon) Showed Potential as Disease-modifying Therapy for Parkinson’s: More Research Needed
"The Cure Parkinson's Trust (CPT) has invested in developing GLP-1 agonists as potential disease-modifying treatments for the last 8 years. With Professor Tom Foltynie we supported and designed the first study of exenatide in people with Parkinson’s that provided the pivotal groundwork for this more recent trial. Importantly we are supporting and shaping the trials that need to follow to ensure ... read more
Source: Published on 2019-01-23